univariate analysis to compare between patients who were and were not on LM. Adverse events due to vaccination were retrospectively collected. Results: 122 patients met inclusion criteria (median age, 58 years; range, 34-75; 52% males). Median time to vaccination was 12.6 months (range 8.1-26.4) after Auto HCT with 71% on LM and 10% on steroids at initiation. 118 completed the Hae- mophilus influenzae type b (Hib) vaccine series per CDC guide- lines. With 24% starting immune and 2% not evaluable, 71% responded (95% of evaluable). Complete pneumococcal vaccination with Prevnar 13 occurred in 119. All patients had lost their im- munity prior to vaccination, but 58% responded to the vaccine (58% of evaluable). 109 patients completed the Polio vaccine series. With 69% retaining immunity, 27% responded to the inactivated polio vaccine (100% of evaluable). 106 completed the full Tdap vaccine series. Tetanus, diphtheria, and pertussis had 60%, 69%, and 75% responders (96, 74, 91% of evaluable), with 32%, 0% and 13% starting immune, respectively. Fewer patients received and completed the Hepatitis A and B vaccines with 76 patients receiving the Hepatitis A vaccine as single agent vaccine or as combined Twinrix (56 completing), and 87 patients receiving the Hepatitis B vaccine as either single agent or combined Twinrix (68 completing). Responses occurred in 30% and 40% (58 & 49% of evaluable), with 29% and 3% starting immune, respectively. Univariate anal- ysis did not show any difference in response rates between the pa- tients who were and were not receiving LM at the time of immunization. The response rates in our cohort are consistent with reports in patients without myeloma. No patients had related adverse events. Conclusions: Re-immunization with inactivated vaccines in patients on LM is both safe and effective, offering this population immunity to vaccine preventable diseases. PS-148 (d) Predictors of Early Treatment Failure following initial therapy for Systemic Immunoglobulin Light Chain Amyloidosis Nidhi Tandon, 1 Surbhi Sidana, 2 Angela Dispenzieri, 1 Morie A. Gertz, 2 Martha Lacy, 2 Francis Buadi, 3 David Dingli, 4 Suzanne Hayman, 3 Amie Fonder, 3 Miriam Hobbs, 3 Wilson Gonsalves, 3 Prashant Kapoor, 4 Robert Kyle, 3 Yi Lisa Hwa, 5 Nelson Leung, 5 Ronald Go, 5 John Lust, 5 Stephen Russell, 5 Steven Zeldenrust, 5 S. Vincent Rajkumar, 5 Shaji Kumar 2 1 Mayo Clinic; 2 Mayo Clinic, Rochester, MN; 3 Mayo Clinic, Rochester, MN; 4 Mayo Clinic, Rochester, MN; 5 Mayo Clinic, Rochester, MN Introduction: The prognosis of patients (pts) with systemic light chain (AL) amyloidosis depends on number and severity of organ involvement, especially cardiac. Though the outcomes have improved over the decades, still the high early mortality remains unchanged. We analyzed the factors predicting early treatment failure (ETF) within 12 and 24 months after 1st therapy for AL amyloidosis. Methods: Pts with AL amyloidosis seen at our institute within 90 days of diagnosis, between 2006 and 2015, were iden- tified. Their data was collected by chart review for retrospective analysis. Pts who died within 3 months of starting therapy were excluded. ETF was defined as relapse / progression requiring treatment change / re-institution or death within 12 (ETF 12) or 24 (ETF 24) months of starting 1st line treatment. Non-ETF included pts with a follow up of more than 12 or 24 months who had relapse/ progression beyond 12 or 24 months or had continuing response. Results: A total of 794 pts met the study criteria and were included in the analysis. Among these, 265 (33.4%) pts had ETF12 and 418 (52.6%) had ETF24, while the rest belonged to Non-ETF12 and 24 cohorts. The median age (64.3 vs 62.3 years; p¼0.01), pro- portion of males (70.5 vs 59.9%; p¼0.003), cardiac involvement (81.3 vs 63.7%; p<0.0001), renal involvement (57.2 vs 68.2 %; p¼0.006), multi-organ involvement (65.6 vs 52.7%; p¼0.0008), presence of t(11; 14) (56.1 vs 42.9 %; p¼0.008) and proportion of pts in higher mayo stage (59.8 vs 41.5; p<0.0001) were higher in ETF12 as compared to Non- ETF12, while liver involvement (17.1 vs 12.1%; p¼0.1) and bone marrow plasma cell (BMPC)% (32.4 vs 31.6%; p¼0.8) were similar. The median follow up was 62.9 months (95% CI; 59.9, 67.3) from start of initial therapy. The variables included in the analyses for factors predicting ETF12 and 24 were age at diagnosis ( vs > 70 years), mayo stage (I+ II vs III+IV), BMPC ( 10% vs > 10%), presence of t(11; 14) versus not, multi-organ involvement (>1 vs 1; heart, liver, kidney, gastrointestinal tract, autonomic neuropathy), incorporation of ASCT in initial therapy. In univariate analysis, t(11; 14), mayo stage, multi-organ involvement, and inclusion of ASCT as part of initial therapy were significantly associated with ETF12 and 24. In multivariate analysis, presence of t(11; 14) and non- incorporation of ASCT as part of initial therapy are significant predictors of ETF12 (p¼0.008 and p¼0.0015, respectively) and ETF24 (p<0.0001 and p¼0.003, respectively) while mayo stage is pre- dictive of ETF24 (p¼0.002), but not ETF12. Conclusions: We demonstrate that pts with ETF are older with higher prevalence of cardiac, renal involvement and multi-organ involvement and higher proportion of patients with t (11; 14) or in Mayo stage (III and IV). Presence of t(11; 14) and non- incorporation of ASCT as part of initial therapy are significant predictors of ETF at 12 or 24 months. PS-149 Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma Hasib Sidiqi, 1 Scott McGregor, 2 Ross Baker, 2 Ben Carnley, 2 Dejan Radeski, 3 Allison Barraclough, 3 Bradley Augustson 3 1 Sir Charles Gairdner Hospital, Perth; 2 Perth Blood Institute; 3 Sir Charles Gairdner Hospital Introduction: Elotuzumab is a humanised monoclonal antibody to SLAMF7, a cell surface receptor that belongs to the signalling- lymphocyte-activation-molecule (SLAM) family, found on multiple Abstracts 16 th International Myeloma Workshop March 1-4, 2017 - e83